These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23456908)

  • 1. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J; Singh J; Istwan N; Rhea D; Driggers RW
    Am J Perinatol; 2014 Jan; 31(1):55-60. PubMed ID: 23456908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
    Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
    Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
    Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
    Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
    Rafael TJ; Mackeen AD; Berghella V
    Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
    Wood SL; Williams BN; Szychowski JM; Owen J
    Am J Perinatol; 2020 Jun; 37(7):659-665. PubMed ID: 31756763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
    Szychowski JM; Berghella V; Owen J; Hankins G; Iams JD; Sheffield JS; Perez-Delboy A; Wing DA; Guzman ER;
    J Matern Fetal Neonatal Med; 2012 Dec; 25(12):2686-9. PubMed ID: 22889234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
    Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
    Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
    Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.